肺癌的基因组学:对ctDNA在非高级非小细胞肺癌中在多模式治疗方法后预后中的作用的范围审查
Carolina Sassorossi1, Jessica Evangelista1,2, Alessio Stefani3
1Thoracic Surgery, Department of thoracic surgery, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Genes
|August 28, 2025
概括
循环瘤DNA (ctDNA) 是早期非小细胞肺癌 (NSCLC) 的基因组生物标志物. 液体活检有助于监测最小残留疾病并预测治疗后的复发.
科学领域:
- 癌症学
- 基因组学
- 生物标志物发现
背景情况:
- 循环瘤DNA (ctDNA) 主要用于晚期非小细胞肺癌 (NSCLC).
- 新兴研究探讨了ctDNA在早期NSCLC的多组方法中的作用.
- 基因组整合正在研究早期NSCLC的手术,预后和复发预测.
研究的目的:
- 审查ctDNA在早期NSCLC治疗中的临床实用性的证据.
- 突出ctDNA作为基因组生物标记物的潜力.
- 评估ctDNA在指导治疗和监测复发中的作用.
主要方法:
- 在PubMed (2000-2024) 上进行广泛的文献搜索.
- 使用的关键词:ctDNA,早期的NSCLC.
- 对符合纳入标准的20项研究进行分析.
主要成果:
- 越来越多的证据支持ctDNA在早期NSCLC的临床使用.
- 基线ctDNA水平提供了关于瘤分子生物学和组织学的见解.
- 液体活检对于追踪最小残留疾病和预测复发后的干预非常有价值.
- 未来的辅助治疗决定可能包括液体活检结果.
结论:
- 在早期的NSCLC治疗中,ctDNA为整合基因组数据提供了新的机会.
- ctDNA可以比传统方法更准确,更具创新性的复发监测.
- 液体活检对早期的NSCLC患者来说特别有前途.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448


